In another study of dyslipidemic patients not treated with hypolipidemic drugs (baseline examination), a very good correlation between LDL-C and apoB (r = 0.903; p < 0.001) was found. [66] In spite of ...

Target levels of LDL cholesterol keep going down, but should we use higher doses of statins to achieve those goals? Hydroxymethylglutaryl- coenzyme A (HMG-CoA) reductase inhibitors, otherwise known as ...

An experimental pill called enlicitide was found to dramatically lower LDL (“bad”) cholesterol by ~60% in a large phase 3 clinical trial. The study ...

Adults with a history of or at risk for a first atherosclerotic cardiovascular disease (ASCVD) event who received the oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor enlicitide ...

A new daily pill could reduce bad cholesterol levels by 60%, according to a new study. Enlicitide, which was developed by Merck, lowered “bad” LDL cholesterol by more than half in a global study ...

A once-a-day tablet called enlicitide is reshaping expectations for cholesterol care, cutting low density lipoprotein, or ...

In this randomized controlled trial, once-daily oral enlicitide was associated with sustained reductions in low-density lipoprotein cholesterol levels compared to placebo among those at high risk of ...

“Bad,” or LDL, cholesterol is a major risk factor for heart disease and most people are screened for it as part of their ...

Once-daily obicetrapib (NewAmsterdam Pharma)—an investigational, highly-selective cholesteryl ester transfer protein (CETP) inhibitor—safely lowers LDL-cholesterol levels on its own and in combination ...

Patients who reach lower levels of LDL cholesterol in the years following DES implantation for STEMI are less likely to develop neoatherosclerosis, a known cause of stent failure, according to a post ...

Please provide your email address to receive an email when new articles are posted on . CETP inhibition may help high-risk patients reach their LDL goals and reduce risk for atherosclerotic CVD events ...

EDIT-401 is an experimental, potentially transformative in vivo gene editing medicine, based on Editas’ differentiated upregulation approach. EDIT-401 is designed to treat hyperlipidemia by directly ...